FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Wants Labeling Changes for Buprenorphine

[ Price : $8.95]

FDA recommends that companies making transmucosal buprenorphine drugs indicated to treat opioid dependence revise the labeling to ...

Global Unique Device ID Database Guidance

[ Price : $8.95]

FDA publishes an updated Global Unique Device Identification Database guidance.

CGMP Violations in Micro Orgo Chem Inspection

[ Price : $8.95]

FDA warns Indias Micro Orgo Chem about CGMP deviations in its production of active pharmaceutical ingredients.

Guide on Drug Batch Uniformity and Integrity

[ Price : $8.95]

FDA posts a draft guidance entitled Considerations for Complying With 21 CFR 211.110 that describes how to comply with batch unifo...

Chimerix NDA for Glioma Drug

[ Price : $8.95]

Chimerix files an NDA seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diff...

Axsome Plans Alzheimers NDA on Mixed Data

[ Price : $8.95]

Axsome Therapeutics plans an NDA submission for AXS-05 (dextromethorphan-bupropion) in the second half of next year for treating A...

Exclude Liraglutide from Compounding: Novo Nordisk

[ Price : $8.95]

Novo Nordisk petitions FDA to exclude its liraglutide from the agencys list of bulk drug substances that may be used by drug compo...

Mylan 6-Item Form FDA-483 Posted

[ Price : $8.95]

FDA posts a six-item Form FDA-483 that led to a 12/19 Warning Letter to Mylan Laboratories citing its Pradesh, India manufacturing...

FDA Approves Checkpoints Unloxcyt

[ Price : $8.95]

FDA approves Checkpoint Therapeutics Unloxcyt to treat some squamous cell cancer patients.

FDA Approves Xcoverys Ensacove for Some Lung Cancers

[ Price : $8.95]

FDA approves Xcoverys Ensacove, an anaplastic lymphoma kinase inhibitor, to treat some non-small cell lung cancers.